Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry
Abstract
:1. Introduction
2. Methods
2.1. Study Design and Population
2.2. Stent Selection
2.3. Clinical Outcomes and Definition
2.4. Statistical Analysis
3. Results
3.1. Baseline Characteristics of the Study Population
3.2. Clinical Outcomes According to Polymer Durability
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Moses, J.W.; Carlier, S.; Moussa, I. Lesion preparation prior to stenting. Rev. Cardiovasc. Med. 2004, 5 (Suppl. S2), S16–S21. [Google Scholar] [PubMed]
- Tan, K.; Sulke, N.; Taub, N.; Sowton, E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: Current experience. J. Am. Coll. Cardiol. 1995, 25, 855–865. [Google Scholar] [CrossRef] [Green Version]
- Madhavan, M.V.; Tarigopula, M.; Mintz, G.S.; Maehara, A.; Stone, G.W.; Généreux, P. Coronary artery calcification: Pathogenesis and prognostic implications. J. Am. Coll. Cardiol. 2014, 63, 1703–1714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomey, M.I.; Kini, A.S.; Sharma, S.K. Current Status of Rotational Atherectomy. JACC Cardiovasc. Interv. 2014, 7, 345–353. [Google Scholar] [CrossRef] [Green Version]
- Reifart, N.; Vandormael, M.; Krajcar, M.; Gohring, S.; Preusler, W.; Schwarz, F.; Storger, H.; Hofmann, M.; Klopper, J.; Muller, S.; et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation 1997, 96, 91–98. [Google Scholar] [CrossRef]
- Moussa, I.; Di Mario, C.; Moses, J.; Reimers, B.; Di Francesco, L.; Martini, G.; Tobis, J.; Colombo, A. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clin-ical follow-up results. Circulation 1997, 96, 128–136. [Google Scholar] [CrossRef] [PubMed]
- Khattab, A.A.; Otto, A.; Hochadel, M.; Toelg, R.; Geist, V.; Richardt, G. Drug-Eluting Stents Versus Bare Metal Stents Following Rotational Atherectomy for Heavily Calcified Coronary Lesions: Late Angiographic and Clinical Follow-Up Results. J. Interv. Cardiol. 2007, 20, 100–106. [Google Scholar] [CrossRef] [PubMed]
- Mezilis, N.; Dardas, P.; Ninios, V.; Tsikaderis, D. Rotablation in the Drug Eluting Era: Immediate and Long-Term Results from a Single Center Experience. J. Interv. Cardiol. 2010, 23, 249–253. [Google Scholar] [CrossRef] [PubMed]
- Abdel-Wahab, M.; Baev, R.; Dieker, P.; Kassner, G.; Khattab, A.A.; Toelg, R.; Sulimov, D.; Geist, V.; Richardt, G. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions. Catheter. Cardiovasc. Interv. 2012, 81, 285–291. [Google Scholar] [CrossRef] [PubMed]
- Jinnouchi, H.; Kuramitsu, S.; Shinozaki, T.; Kobayashi, Y.; Hiromasa, T.; Morinaga, T.; Mazaki, T.; Sakakura, K.; Soga, Y.; Hyodo, M.; et al. Two-Year Clinical Outcomes of Newer-Generation Drug-Eluting Stent Implantation Following Rotational Atherectomy for Heavily Calcified Lesions. Circ. J. 2015, 79, 1938–1943. [Google Scholar] [CrossRef] [PubMed]
- Matsunaga-Lee, Y.; Tanaka, A.; Mori, N.; Yoshimura, T.; Nakamura, D.; Taniike, M.; Makino, N.; Egami, Y.; Shutta, R.; Tanouchi, J.; et al. Thin-strut drug-eluting stents are more favorable for severe calcified lesions after rotational atherectomy than thick-strut drug-eluting stents. J. Invasive Cardiol. 2014, 26, 41–45. [Google Scholar]
- Rathore, S.; Matsuo, H.; Terashima, M.; Kinoshita, Y.; Kimura, M.; Tsuchikane, E.; Nasu, K.; Ehara, M.; Asakura, Y.; Katoh, O.; et al. Rotational atherectomy for fibro-calcific coronary artery disease in drug eluting stent era: Procedural outcomes and angiographic follow up results. Catheter. Cardiovasc. Interv. 2010, 75, 919–927. [Google Scholar] [CrossRef] [PubMed]
- Buiten, R.A.; Ploumen, E.; Zocca, P.; Doggen, C.J.M.; Van Der Heijden, L.C.; Kok, M.M.; Danse, P.W.; Schotborgh, C.E.; Scholte, M.; De Man, F.H.A.F.; et al. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. JAMA Cardiol. 2019, 4, 659–669. [Google Scholar] [CrossRef] [PubMed]
- Buiten, R.A.; Ploumen, E.; Zocca, P.; Doggen, C.J.M.; Van Houwelingen, K.G.; Danse, P.W.; Schotborgh, C.E.; Stoel, M.G.; Scholte, M.; Linssen, G.C.M.; et al. Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial. Catheter. Cardiovasc. Interv. 2020, 96, E508–E515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kandzari, D.E.; Koolen, J.J.; Doros, G.; Garcia-Garcia, H.M.; Bennett, J.; Roguin, A.; Gharib, E.G.; Cutlip, D.E.; Waksman, R. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. JACC Cardiovasc. Interv. 2020, 13, 1343–1353. [Google Scholar] [CrossRef] [PubMed]
- Pilgrim, T.; Muller, O.; Heg, D.; Roffi, M.; Kurz, D.J.; Moarof, I.; Weilenmann, D.; Kaiser, C.; Tapponnier, M.; Losdat, S.; et al. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial. JACC Cardiovasc. Interv. 2021, 14, 639–648. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.; Jung, J.-H.; Lee, M.; Kim, D.-W.; Park, M.-W.; Choi, I.-J.; Lee, J.-H.; Lee, J.-H.; Lee, S.-R.; Lee, P.-H.; et al. Clinical Outcome of Rotational Atherectomy in Calcified Lesions in Korea-ROCK Registry. Medicina 2021, 57, 694. [Google Scholar] [CrossRef]
- Chesebro, J.H.; Knatterud, G.; Roberts, R.; Borer, J.; Cohen, L.S.; Dalen, J.; Dodge, H.T.; Francis, C.K.; Hillis, D.; Ludbrook, P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987, 76, 142–154. [Google Scholar] [CrossRef] [Green Version]
- Austin, P.C. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar. Behav. Res. 2011, 46, 399–424. [Google Scholar] [CrossRef] [Green Version]
- Peduzzi, P.; Concato, J.; Feinstein, A.R.; Holford, T.R. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J. Clin. Epidemiol. 1995, 48, 1503–1510. [Google Scholar] [CrossRef]
- Okai, I.; Dohi, T.; Okazaki, S.; Jujo, K.; Nakashima, M.; Otsuki, H.; Tanaka, K.; Arashi, H.; Okabe, R.; Nagura, F.; et al. Clinical Characteristics and Long-Term Outcomes of Rotational Atherectomy—J2T Multicenter Registry. Circ. J. 2018, 82, 369–375. [Google Scholar] [CrossRef] [PubMed]
- Lange, R.A.; Hillis, L.D. Second-Generation Drug-Eluting Coronary Stents. N. Engl. J. Med. 2010, 362, 1728–1730. [Google Scholar] [CrossRef] [PubMed]
- Stefanini, G.G.; Holmes, D.R., Jr. Drug-Eluting Coronary-Artery Stents. N. Engl. J. Med. 2013, 368, 254–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stone, G.W.; Rizvi, A.; Newman, W.; Mastali, K.; Wang, J.C.; Caputo, R.; Doostzadeh, J.; Cao, S.; Simonton, C.A.; Sudhir, K.; et al. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. N. Engl. J. Med. 2010, 362, 1663–1674. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, Y.; Okura, H.; Kume, T.; Yamada, R.; Kobayashi, Y.; Fukuhara, K.; Koyama, T.; Nezuo, S.; Neishi, Y.; Hayashida, A.; et al. Impact of Target Lesion Coronary Calcification on Stent Expansion. Circ. J. 2014, 78, 2209–2214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lindsay, A.C.; Paulo, M.; Kadriye, K.; Tejeiro, R.; Alegría-Barrero, E.; Chan, P.H.; Foin, N.; Syrseloudis, D.; Di Mario, C. Predictors of stent strut malapposition in calcified vessels using frequency-domain optical coherence tomography. J. Invasive Cardiol. 2013, 25, 429–434. [Google Scholar] [PubMed]
- Guedeney, P.; Claessen, B.E.; Mehran, R.; Mintz, G.S.; Liu, M.; Sorrentino, S.; Giustino, G.; Farhan, S.; Leon, M.B.; Serruys, P.W.; et al. Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. JACC Cardiovasc. Interv. 2020, 13, 1417–1428. [Google Scholar] [CrossRef] [PubMed]
- Inoue, T.; Croce, K.; Morooka, T.; Sakuma, M.; Node, K.; Simon, D.I. Vascular Inflammation and Repair: Implications for Re-Endothelialization, Restenosis, and Stent Thrombosis. JACC Cardiovasc. Interv. 2011, 4, 1057–1066. [Google Scholar] [CrossRef] [Green Version]
- Bangalore, S.; Toklu, B.; Patel, N.; Feit, F.; Stone, G.W. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. Circulation 2018, 138, 2216–2226. [Google Scholar] [CrossRef]
- Palmerini, T.; Biondi-Zoccai, G.; Della Riva, D.; Mariani, A.; Sabaté, M.; Smits, P.C.; Kaiser, C.; D’Ascenzo, F.; Frati, G.; Mancone, M.; et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. J. Am. Coll. Cardiol. 2014, 63, 299–307. [Google Scholar] [CrossRef] [Green Version]
- El-Hayek, G.; Bangalore, S.; Dominguez, A.C.; Devireddy, C.; Jaber, W.; Kumar, G.; Mavromatis, K.; Tamis-Holland, J.; Samady, H. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc. Interv. 2017, 10, 462–473. [Google Scholar] [CrossRef] [PubMed]
- Kuriyama, N.; Kobayashi, Y.; Yamaguchi, M.; Shibata, Y. Usefulness of Rotational Atherectomy in Preventing Polymer Damage of Everolimus-Eluting Stent in Calcified Coronary Artery. JACC Cardiovasc. Interv. 2011, 4, 588–589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abdel-Wahab, M.; Richardt, G.; Büttner, H.J.; Toelg, R.; Geist, V.; Meinertz, T.; Schofer, J.; King, L.; Neumann, F.-J.; Khattab, A.A. High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions: The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial. JACC Cardiovasc. Interv. 2013, 6, 10–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mankerious, N.; Hemetsberger, R.; Traboulsi, H.; Toelg, R.; Abdel-Wahab, M.; Richardt, G.; Allali, A. Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy. Clin. Res. Cardiol. 2021, 110, 1574–1585. [Google Scholar] [CrossRef] [PubMed]
Before PS Matching | After PS Matching | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Characteristics | DP-DES (n = 272) | BP-DES (n = 238) | p-Value | SMD | DP-DES (n = 201) | BP-DES (n = 201) | p-Value | SMD | ||
Demographic and clinical characteristics | ||||||||||
Age (years) | 74 (66, 78) | 73 (64, 79) | 0.373 | 0.084 | 74 (66, 78) | 73 (64, 79) | 0.636 | 0.062 | ||
Sex (Male, %) | 150 (55.1) | 156 (65.5) | 0.021 | 0.214 | 127 (63.2) | 126 (62.7) | 1.000 | 0.010 | ||
BMI (kg/m2) | 23.7 (21.7, 26.1) | 24.0 (22.1, 27.0) | 0.291 | 0.051 | 23.8 (22.5, 25.7) | 23.8 (22.2, 26.9) | 0.780 | 0.021 | ||
HTN (%) | 216 (79.4) | 183 (76.9) | 0.561 | 0.061 | 159 (79.1) | 159 (79.1) | 1.000 | <0.001 | ||
DM (%) | 146 (53.7) | 141 (59.2) | 0.240 | 0.112 | 116 (57.7) | 118 (58.7) | 0.919 | 0.020 | ||
Smoking (%) | 48 (17.6) | 51 (21.4) | 0.335 | 0.095 | 38 (18.9) | 42 (20.9) | 0.708 | 0.050 | ||
Dyslipidemia (%) | 125 (46.0) | 104 (43.7) | 0.673 | 0.045 | 90 (44.8) | 90 (44.8) | 1.000 | <0.001 | ||
CKD (%) | 48 (17.6) | 50 (21.0) | 0.396 | 0.085 | 34 (16.9) | 34 (16.9) | 1.000 | <0.001 | ||
Dialysis (%) | 25 (9.2) | 27 (11.3) | 0.512 | 0.071 | 16 (8.0) | 17 (8.5) | 1.000 | 0.018 | ||
Previous PCI (%) | 68 (25.0) | 66 (27.7) | 0.550 | 0.062 | 56 (27.9) | 49 (24.4) | 0.496 | 0.079 | ||
Previous MI (%) | 29 (10.7) | 33 (13.9) | 0.333 | 0.098 | 26 (12.9) | 24 (11.9) | 0.88 | 0.030 | ||
Previous CVA (%) | 33 (12.1) | 29 (12.2) | 1.000 | 0.002 | 27 (13.4) | 26 (12.9) | 1.000 | 0.015 | ||
Atrial fibrillation (%) | 26 (9.6) | 21 (8.8) | 0.894 | 0.025 | 19 (9.5) | 19 (9.5) | 1.000 | <0.001 | ||
SBP (mmHg) | 130 (120, 140) | 130 (120, 145) | 0.310 | 0.065 | 130 (120, 140) | 129 (120, 140) | 0.797 | 0.019 | ||
DBP (mmHg) | 77 (67, 80) | 74 (66, 80) | 0.844 | 0.029 | 77 (66, 80) | 74 (66, 80) | 0.888 | 0.065 | ||
Laboratory findings | ||||||||||
LVEF (%) | 57.0 (46.0, 63.0) | 57.0 (42.0, 63.0) | 0.123 | 0.138 | 57.0 (45.0, 62.0) | 57.0 (42.0, 63.0) | 0.950 | 0.041 | ||
Hb (mg/dL) | 12.1 ±1.8 | 12.4 ± 1.9 | 0.122 | 0.137 | 12.2 ± 1.8 | 12.4 ± 1.9 | 0.350 | 0.093 | ||
Platelet (109/L) | 223 ± 70.9 | 218 ± 72.8 | 0.491 | 0.061 | 210 (170, 248) | 213 (165, 264) | 0.526 | 0.066 | ||
HbA1c (%) | 6.3 (5.7, 7.3) | 6.3 (5.7, 7.1) | 0.782 | 0.048 | 6.4 (5.7, 7.2) | 6.2 (5.7, 7.1) | 0.675 | 0.012 | ||
LDL-cholesterol (mg/dL) | 83.0 (63.2, 100.5) | 75.1 (59.2, 101.1) | 0.229 | 0.061 | 79.0 (61.0, 96.7) | 79.0 (60.5, 102.2) | 0.723 | 0.059 | ||
Initial Cr (mg/dL) | 0.90 (0.73, 1.22) | 0.93 (0.80, 1.22) | 0.043 | 0.216 | 0.91 (0.74, 1.28) | 0.91 (0.78, 1.14) | 0.794 | 0.008 | ||
Peak CK-MB (ng/mL) | 6.90 (3.10, 19.30) | 3.86 (1.90, 12.52) | <0.001 | 0.072 | 6.96 (3.30, 18.83) | 4.12 (2.02, 15.38) | 0.011 | 0.011 | ||
Angiographic and procedural characteristics | ||||||||||
Diagnosis (%) | 0.607 | 0.146 | 0.998 | 0.034 | ||||||
SA | 94 (34.6) | 83 (34.9) | 68 (33.8) | 68 (33.8) | ||||||
UA | 90 (33.1) | 70 (29.4) | 66 (32.8) | 65 (32.3) | ||||||
NSTEMI | 66 (24.3) | 57 (23.9) | 45 (22.4) | 46 (22.9) | ||||||
STEMI | 9 (3.3) | 9 (3.8) | 9 (4.5) | 8 (4.0) | ||||||
Silent ischemia | 13 (4.8) | 19 (8.0) | 13 (6.5) | 14 (7.0) | ||||||
Coronary artery (%) | 0.545 | 0.097 | 0.705 | 0.083 | ||||||
LAD | 188 (69.1) | 159 (66.8) | 140 (69.7) | 133 (66.2) | ||||||
LCX | 19 (7.0) | 23 (9.7) | 17 (8.5) | 21 (10.4) | ||||||
RCA | 65 (23.9) | 56 (23.5) | 44 (21.9) | 47 (23.4) | ||||||
Multivessel disease (%) | 107 (84.3) | 137 (76.5) | 0.131 | 0.195 | 182 (90.5) | 177 (88.1) | 0.519 | 0.081 | ||
LM disease (%) | 42 (15.4) | 36 (15.1) | 1.000 | 0.009 | 35 (17.4) | 31 (15.4) | 0.686 | 0.054 | ||
Stent (%) | ||||||||||
BES-BP | 0 (0.0) | 12 (5.1) | 0 (0.0) | 11 (5.5) | ||||||
CoCr-SES-BP | 0 (0.0) | 75 (31.6) | 0 (0.0) | 65 (32.5) | ||||||
PtCr-EES-BP | 0 (0.0) | 150 (63.3) | 0 (0.0) | 124 (62.0) | ||||||
CoCr-EES-DP | 99 (36.4) | 0 (0.0) | 75 (37.3) | 0 (0.0) | ||||||
PtCr-EES-DP | 80 (29.4) | 0 (0.0) | 54 (26.9) | 0 (0.0) | ||||||
ZES-DP | 93 (34.2) | 0 (0.0) | 72 (35.8) | 0 (0.0) | ||||||
Mean stent diam. (mm) | 3.00 (2.75, 3.25) | 2.92 (2.75, 3.23) | 0.640 | 0.018 | 3.00 (2.75, 3.28) | 2.89 (2.75, 3.23) | 0.595 | 0.033 | ||
Total stent length (mm) | 46 (34, 61) | 51 (33, 66) | 0.222 | 0.085 | 46 (38, 60) | 51 (33, 66) | 0.528 | 0.028 | ||
Number of stents | 2 (1, 2) | 2 (1, 2) | 0.865 | 0.063 | 2 (1, 2) | 2 (1, 2) | 0.734 | 0.075 | ||
Max. burr diam. (mm) | 1.50 (1.50, 1.50) | 1.50 (1.25, 1.50) | 0.609 | 0.038 | 1.50 (1.50, 1.50) | 1.50 (1.25, 1.50) | 0.612 | 0.037 | ||
IVUS (%) | 111 (40.8) | 135 (56.7) | <0.001 | 0.322 | 100 (49.8) | 108 (53.7) | 0.485 | 0.080 | ||
Medication at discharge | ||||||||||
Aspirin (%) | 265 (98.1) | 234 (98.3) | 1.000 | † | 0.013 | 198 (98.5) | 197 (98.0) | 1.000 | † | 0.038 |
P2Y12 inhibitor (%) | 266 (98.5) | 237 (99.6) | 0.378 | † | 0.110 | 199 (99.0) | 201 (100.0) | 0.499 | † | 0.142 |
RASB (%) | 198 (73.3) | 170 (71.4) | 0.704 | 0.148 | 144 (71.6) | 142 (70.6) | 0.912 | 0.022 | ||
BB (%) | 176 (65.2) | 138 (58.0) | 0.115 | 0.043 | 125 (62.2) | 121 (60.2) | 0.759 | 0.041 | ||
Statin (%) | 246 (91.8) | 227 (95.4) | 0.147 | 0.147 | 187 (93.0) | 190 (94.5) | 0.680 | 0.062 |
DP-DES n (%) | BP-DES n (%) | Crude | PSM | |||
---|---|---|---|---|---|---|
HR (CI) | p-Value | HR (CI) | p-Value | |||
All-cause death | 29 (10.7) | 11 (4.7) | 0.539 (0.267–1.090) | 0.085 | 0.414 (0.174–0.988) | 0.047 |
Cardiovascular death | 22 (8.1) | 8 (3.4) | 0.490 (0.217–1.108) | 0.087 | 0.281 (0.094–0.843) | 0.024 |
Target lesion failure | 37 (13.6) | 29 (12.2) | 1.155 (0.705–1.891) | 0.567 | 1.048 (0.590–1.861) | 0.874 |
Univariate | Multivariate | ||||
---|---|---|---|---|---|
Characteristics | HR (CI) | p-Value | HR (CI) | p-Value | |
Polymer | 0.085 | * | 0.033 | ||
DP-DES | reference | reference | |||
BP-DES | 0.539 (0.267–1.090) | 0.458 (0.224–0.940) | |||
Age | 1.054 (1.019–1.089) | 0.002 | * | 1.048 (1.008–1.088) | 0.017 |
Sex (Male) | 0.794 (0.448–1.408) | 0.430 | |||
BMI | 0.818 (0.741–0.903) | <0.001 | * | ||
HTN | 0.838 (0.435–1.614) | 0.597 | |||
DM | 1.165 (0.650–2.086) | 0.608 | |||
Smoking | 0.949 (0.459–1.963) | 0.888 | |||
Dyslipidemia | 0.521 (0.282–0.963) | 0.037 | * | ||
CKD | 1.276 (0.634–2.571) | 0.495 | |||
Dialysis | 0.679 (0.211–2.187) | 0.516 | |||
Previous PCI | 0.788 (0.401–1.548) | 0.488 | |||
Previous MI | 0.887 (0.351–2.242) | 0.801 | |||
Previous CVA | 2.705 (1.427–5.127) | 0.002 | * | 2.656 (1.294–5.451) | 0.008 |
Atrial fibrillation | 1.606 (0.719–3.585) | 0.248 | |||
SBP | 0.999 (0.986–1.011) | 0.820 | |||
DBP | 1.001 (0.976–1.024) | 0.981 | |||
LVEF | 0.965 (0.947–0.984) | <0.001 | * | 0.966 (0.945–0.987) | 0.002 |
Hb | 0.736 (0.626–0.866) | <0.001 | * | ||
Platelet | 1.001 (0.997–1.005) | 0.773 | |||
HbA1c | 1.089 (0.878–1.349) | 0.438 | |||
LDL-cholesterol | 1.002 (0.994–1.009) | 0.649 | |||
Initial Cr | 0.923 (0.766–1.112) | 0.397 | |||
Peak CK-MB | 1.008 (1.003–1.013) | <0.001 | * | 1.007 (1.001–1.012) | 0.012 |
Diagnosis | |||||
SA | reference | * | |||
UA | 2.610 (0.980–6.955) | 0.055 | |||
NSTEMI | 6.253 (2.546–15.385) | <0.001 | |||
STEMI | 1.928 (0.232–16.016) | 0.543 | |||
Silent Ischemia | 5.601 (1.708–18.369) | 0.004 | |||
Coronary artery | |||||
LAD | reference | ||||
LCX | 0.861 (0.304–2.436) | 0.778 | |||
RCA | 0.885 (0.446–1.757) | 0.727 | |||
Multivessel disease | 1.654 (0.495–5.528) | 0.414 | |||
LM disease | 0.907 (0.406–2.025) | 0.812 | |||
Mean stent diameter | 0.363 (0.145–0.911) | 0.031 | * | ||
Number of stents | 1.168 (0.921–1.481) | 0.202 | |||
Total stent length | 1.005 (0.996–1.013) | 0.255 | |||
Max. burr diameter | 0.415 (0.108–2.215) | 0.303 | |||
IVUS | 0.573 (0.313–1.049) | 0.071 | * | ||
Aspirin | 0.212 (0.066–0.685) | 0.010 | * | ||
P2Y12 inhibitor | 0.039 (0.014–0.109) | <0.001 | * | 0.011 (0.003–0.042) | <0.001 |
RASB | 0.733 (0.408–1.315) | 0.297 | |||
BB | 0.383 (0.214–0.685) | 0.001 | * | ||
Statin | 0.243 (0.113–0.521) | <0.001 | * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, K.A.; Her, S.-H.; Lee, K.; Choi, I.J.; Lee, J.-H.; Lee, J.H.; Lee, S.R.; Lee, P.H.; Lee, S.-W.; Yoo, K.D.; et al. Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry. J. Clin. Med. 2022, 11, 6251. https://doi.org/10.3390/jcm11216251
Kim KA, Her S-H, Lee K, Choi IJ, Lee J-H, Lee JH, Lee SR, Lee PH, Lee S-W, Yoo KD, et al. Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry. Journal of Clinical Medicine. 2022; 11(21):6251. https://doi.org/10.3390/jcm11216251
Chicago/Turabian StyleKim, Kyung An, Sung-Ho Her, Kyusup Lee, Ik Jun Choi, Jae-Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Pil Hyung Lee, Seung-Whan Lee, Ki Dong Yoo, and et al. 2022. "Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry" Journal of Clinical Medicine 11, no. 21: 6251. https://doi.org/10.3390/jcm11216251
APA StyleKim, K. A., Her, S. -H., Lee, K., Choi, I. J., Lee, J. -H., Lee, J. H., Lee, S. R., Lee, P. H., Lee, S. -W., Yoo, K. D., Lee, S. N., Jang, W. Y., Moon, D., Moon, K. -W., Yun, K. H., & Lee, H. -J. (2022). Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry. Journal of Clinical Medicine, 11(21), 6251. https://doi.org/10.3390/jcm11216251